Clinical Trial: Comparing the Hemodiafiltration On-line and Conventional Hemodialysis in Terms of Cost-benefit

Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional

Official Title: Prospective Randomized Study Comparing the Hemodiafiltration On-line and Conventional Hemodialysis in Terms of Cost-benefit

Brief Summary:

The site where the clinical trial will be conducted is at the St-Luc hospital from the CHUM. This is a prospective randomized study that will compare the two treatment modalities, HD and HDF, through economics and pharmaco-economics parameters.

Patients, who had previously been randomized in the CONTRAST study, will remain in their respective group and monitoring will continue. The next patients will be randomized in the same way (1: 1) using the same inclusion and exclusion criteria. HDF randomized patients will receive post-dilution standard reinjection (at least 100ml/min or 6 liter/hr). In rare cases, HDF patients can briefly have reinjection on a pre-dilution mode (if heparin need to be avoided for example) and the reinjection flow should be adjusted accordingly (200ml/min).

Length and frequency of sessions will be the same in the 2 groups. Blood tests will not change and will be the same than those used as routine assessments. Metabolic control of patients will be maintained according to the guidelines. Patients will be monitored for a minimum of 3 years. A set of demographic and clinical data will be collected from patient medical records and throughout the study.

Biochemical data as part of the usual blood tests of dialysis patients will be collected each month as well as will be stored and analyzed information about the annual cardiac ultrasounds.

All events will be scored (hospitalizations, patterns, duration) and the list and cost of drugs will be compiled every three months. These data will be useful in the economic analysis comparing the two treatment modalities.


Detailed Summary:
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)

Current Primary Outcome:

  • compare the medication cost between the 2 groups (HD and HDF) [ Time Frame: 3 years ]
  • demonstrate lower cost of erythropoietin in HDF, with same control of anemia to HD group [ Time Frame: 3 years ]
  • demonstrate lower cost of phosphate binder in HDF, with same control of phospho calcium balance to HD group [ Time Frame: 3 years ]


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • demonstrate lower need of Erythropoietin and best control of anemia in HDF [ Time Frame: 3 years ]
  • demonstrate lower need of phosphate binder and best control of phospho-calcique balance in HDF [ Time Frame: 3 years ]
  • demonstrate less hospitalization stay and cost related in HDF group [ Time Frame: 3 years ]
  • stabilisation or regression of left ventricular hypertrophy [ Time Frame: 3 years ]


Original Secondary Outcome: Same as current

Information By: Centre hospitalier de l'Université de Montréal (CHUM)

Dates:
Date Received: September 24, 2013
Date Started: January 2011
Date Completion: June 2018
Last Updated: February 14, 2017
Last Verified: February 2017